Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine / 中华流行病学杂志

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate the safety and immunogenicity of Canada split influenza virus vaccine.</p><p><b>METHODS</b>Cluster samples were by randomly chosen and divided into split vaccination group and homoimported influenza vaccination group.</p><p><b>RESULTS</b>After injection, fever-reaction and local reaction rates of 'trial' group were found as 3.69% and 1.75% respectively, but no statistical significance was found when compared with 'control' group. However the antibody positive rates of 'trail' and 'control' groupsappeared statistically significant (H1N1 96.8% vs. 92.3%, H3N2 95.8% vs. 90.2%, B 52.3% vs. 62.3%). For geometric mean titer (GMT) of type H1N1, H3H2 and B antibody, 'trial' group and 'control' group increased 22.4, 16.8, 8.2 and 21.2, 12.5 and 7.4 times respectively. The antibody protective rates of type H1N1, H3N2 and B were 99%, 99% and 53.9% for 'trial' group, and 96.2%, 98.4% and 62.3% for 'control' but with no statistically significant difference.</p><p><b>CONCLUSION</b>Influenza split vaccine made in Shire company in Canada was safe and with good immunogenicity.</p>